DUODOPA Enables Your Patients to Continue Their Gold Standard Treatment
For levodopa-responsive patients with complex/advanced Parkinson’s
In a study, DUODOPA provided predictability of ‘ON’ time and ‘OFF’ time2
In a 54-week safety study, patients with severe motor fluctuations on DUODOPA had a significant increase in 'ON' time without troublesome dyskinesia and a significant decrease in 'OFF' time compared with baseline (both p<0.001), which was sustained throughout the study.2
In a study, DUODOPA had a greater effect on total non-motor symptom score than apomorphine3*
In a 6-month study comparing the effects of DUODOPA and apomorphine, increase from baseline in non-motor symptom scale (NMSS) score was:3
- DUODOPA +0.83
- Apomorphine +0.53
- Both treatments had similar efficacy for motor scores and HRQoL
Significant results:3
- Duodopa: Sleep/fatigue (p=0.017);* Gastrointestinal (p=0.004);* Urinary (p=0.0001);* Sexual function (p=0.001)*
- Apomorphine: Mood/apathy (p=0.03)*
In a study, benefits in non-motor symptoms were sustained over a period of two years with DUODOPA4
In a 24-month registry study evaluating safety and efficacy of Duodopa, significant and sustained improvements in motor fluctuations and associated non-motor symptoms were observed (p<0.001)†4
Particularly in:4
- Sleep/fatigue (p<0.001)
- Mood/cognition (p=0.004)
- Gastrointestinal symptoms (p<0.001)
†Improvement measured by reduction from baseline in the mean non-motor symptoms scale (NMSS) scores.
Reliable:
Duodopa offers a reliable solution around the problem of delayed gastric emptying1
Smooth:
The consistent delivery of DUODOPA smooths out any peaks or troughs in plasma concentration1
Adjustable:
Dosing can be individually optimised to suit the patient, over a 16-hour period1
In a 12-week study, advanced PD patients were randomised to receive either OMT (n=33) or DUODOPA (n=28).5
Patients who received DUODOPA had sustained and significant improvements in UDysRS total scores through Week 12 compared to OMT (p<0.001).5
At Week 12, compared to OMT, patients treated with DUODOPA experienced5:
• 3.27 hours more ‘ON’ time without troublesome dyskinesia (3.15 hours with DUODOPA vs -0.12 hours with OMT; p=0.0001)
• 2.35 hours less ‘OFF’ time (-2.17 hours with DUODOPA vs 0.18 hours with OMT; p=0.0002)
Safety & Tolerability
DUODOPA has a well-understood safety profile2
An open-label study shows DUODOPA offers a well-understood adverse event profile2
- For the majority of patients adverse events are mild (19%) or moderate (44%) and transient2
- Low withdrawal rate (8%) due to adverse events, most commonly due to complication of insertion of device2
For more detailed safety information, please refer to the Summary of Product Characteristics (SmPC).
I want to receive more information about DUODOPA
References
- Nyholm D, et al. AAPS J 2013;15:316–23.
- Fernandez HH, et al. Mov Disord 2015;30:500–9.
- Martinez-Martin P, et al. Mov Dis 2015;30:510–6.
- Antonini A, et al. Parkinsonism Relat Disord 2017;45:13–20.
- Alvarez EF, et al. Presented at the MDS Virtual Congress, 12–16 September 2020:867.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-DUOD-210079. Date of preparation: May 2021.